These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis. Maier S; Barcutean L; Andone S; Manu D; Sarmasan E; Bajko Z; Balasa R Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901807 [TBL] [Abstract][Full Text] [Related]
10. Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression. Ibrahim SH; El-Mehdawy KM; Seleem M; El-Sawalhi MM; Shaheen AA J Neuroimmunol; 2020 Oct; 347():577356. PubMed ID: 32781341 [TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Katz Sand I; Krieger S; Farrell C; Miller AE Mult Scler; 2014 Oct; 20(12):1654-7. PubMed ID: 24493475 [TBL] [Abstract][Full Text] [Related]
13. Involvement of cytotoxic Eomes-expressing CD4 Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594 [TBL] [Abstract][Full Text] [Related]
14. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis. Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277 [TBL] [Abstract][Full Text] [Related]
15. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Antel J; Antel S; Caramanos Z; Arnold DL; Kuhlmann T Acta Neuropathol; 2012 May; 123(5):627-38. PubMed ID: 22327362 [TBL] [Abstract][Full Text] [Related]
16. Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey. Alvarez E; Nair KV; Gorritz M; Bartolome L; Maloney H; Ding Y; Golan T; Wade RL; Kumar R; Su W; Shah R; Russo P Mult Scler Relat Disord; 2021 May; 50():102858. PubMed ID: 33799068 [TBL] [Abstract][Full Text] [Related]
17. Natural history of multiple sclerosis: a unifying concept. Confavreux C; Vukusic S Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308 [TBL] [Abstract][Full Text] [Related]
18. miR-24-3p and miR-484 are potential biomarkers for neurodegeneration in multiple sclerosis. Al-Temaimi R; Alroughani R Heliyon; 2024 Jun; 10(12):e32685. PubMed ID: 38975190 [TBL] [Abstract][Full Text] [Related]
19. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views. Ziemssen T; Tolley C; Bennett B; Kilgariff S; Jones E; Pike J; Tomic D; Piani-Meier D; Lahoz R Mult Scler Relat Disord; 2020 Feb; 38():101861. PubMed ID: 31865132 [TBL] [Abstract][Full Text] [Related]
20. A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. Inojosa H; Proschmann U; Akgün K; Ziemssen T J Neurol; 2021 Apr; 268(4):1210-1221. PubMed ID: 31363847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]